Exactly, QB is attainable in 1Q 2017. QX, as Jimmy proposes, is not. The requirements are too high. Also, the company's continued relationship with Midam, as well as undervalued shares, should be addressed in the next conference call, if there is one.
Regarding M&A, one of the most cost efficient tactics is a share swap (which does not imply dilution). Until RXMD raises its market value, a tie-up that leaves it in a stronger or equal position vis-a-vis a peer is out of the question. The only reasonable scenario now is that RXMD is acquired at a discount to fair value. That is, if the inquiries Mars says she receives are from companies actually serious about wanting to own RXMD.
News 
Market Data 
Discover 
